Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial
Pharmacology, Toxicology and Pharmaceutical Science
2
3%
Nursing and Health Professions
2
3%
Other
3
4%
Unknown
23
30%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2025.
All research outputs
#3,807,781
of 34,545,128 outputs
Outputs from Lancet Oncology
#3,231
of 8,015 outputs
Outputs of similar age
#19,249
of 235,032 outputs
Outputs of similar age from Lancet Oncology
#8
of 31 outputs
Altmetric has tracked 34,545,128 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,015 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.3. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,032 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.